Literature DB >> 23929690

Evaluating prodrug strategies for esterase-triggered release of alcohols.

Christian Perez1, Kevin B Daniel, Seth M Cohen.   

Abstract

Prodrugs are effective tools in overcoming drawbacks typically associated with drug formulation and delivery. Those employing esterase-triggered functional groups are frequently utilized to mask polar carboxylic acids and phenols, increasing drug-like properties such as lipophilicity. Herein we detail a comprehensive assessment for strategies that effectively release hydroxy and phenolic moieties in the presence of an esterase. Matrix metalloproteinases (MMPs) serve as our proof-of-concept target. Three distinct ester-responsive protecting groups are incorporated into MMP proinhibitors containing hydroxy moieties. Analytical evaluation of the proinhibitors demonstrates that the use of a benzyl ether group appended to the esterase trigger leads to considerably faster kinetics of conversion and enhanced aqueous stability when compared with more conventional approaches where the trigger is directly attached to the inhibitor. Biological assays confirm that all protecting groups effectively cleave in the presence of esterase to generate the active inhibitor. The superior reaction-based prodrug strategies presented here should serve as a platform for esterase-responsive prodrug design in the future.
Copyright © 2013 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  enzyme‐triggered release; esterases; matrix metalloproteinases; metalloenzymes; prodrugs

Mesh:

Substances:

Year:  2013        PMID: 23929690      PMCID: PMC3918245          DOI: 10.1002/cmdc.201300255

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  23 in total

1.  Design and therapeutic application of matrix metalloproteinase inhibitors.

Authors:  M Whittaker; C D Floyd; P Brown; A J Gearing
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

Review 2.  Prodrugs of biologically active phosphate esters.

Authors:  Carsten Schultz
Journal:  Bioorg Med Chem       Date:  2003-03-20       Impact factor: 3.641

Review 3.  Lessons learned from marketed and investigational prodrugs.

Authors:  Peter Ettmayer; Gordon L Amidon; Bernd Clement; Bernard Testa
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

4.  Prodrugs: Some thoughts and current issues.

Authors:  Valentino J Stella
Journal:  J Pharm Sci       Date:  2010-12       Impact factor: 3.534

Review 5.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Authors:  Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

Review 6.  Prodrugs--from serendipity to rational design.

Authors:  Kristiina M Huttunen; Hannu Raunio; Jarkko Rautio
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

7.  Enzymatic activation of a matrix metalloproteinase inhibitor.

Authors:  Jody L Major Jourden; Seth M Cohen
Journal:  Chem Commun (Camb)       Date:  2010-01-18       Impact factor: 6.222

Review 8.  Strategies for MMP inhibition in cancer: innovations for the post-trial era.

Authors:  Christopher Mark Overall; Carlos López-Otín
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

9.  A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases.

Authors:  C G Knight; F Willenbrock; G Murphy
Journal:  FEBS Lett       Date:  1992-01-27       Impact factor: 4.124

10.  Neuroprotective effect of 4-hydroxybenzyl alcohol against transient focal cerebral ischemia via anti-apoptosis in rats.

Authors:  Shan-Shan Yu; Jing Zhao; Wei-Ping Zheng; Yong Zhao
Journal:  Brain Res       Date:  2009-10-24       Impact factor: 3.252

View more
  9 in total

1.  Exploring hydrogen peroxide responsive thiazolidinone-based prodrugs.

Authors:  Christian Perez; Jean-Philippe Monserrat; Yao Chen; Seth M Cohen
Journal:  Chem Commun (Camb)       Date:  2015-04-28       Impact factor: 6.222

Review 2.  Microbial esterases and ester prodrugs: An unlikely marriage for combating antibiotic resistance.

Authors:  Erik M Larsen; R Jeremy Johnson
Journal:  Drug Dev Res       Date:  2018-10-10       Impact factor: 4.360

3.  Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.

Authors:  Mohamed F Radwan; Kevin N Dalby; Tamer S Kaoud
Journal:  ACS Med Chem Lett       Date:  2014-06-23       Impact factor: 4.345

4.  Structure-Activity Relationship of Heterocyclic P2Y14 Receptor Antagonists: Removal of the Zwitterionic Character with Piperidine Bioisosteres.

Authors:  Young-Hwan Jung; Veronica Salmaso; Zhiwei Wen; John M Bennett; Ngan B Phung; David I Lieberman; Varun Gopinatth; John C R Randle; Zhoumou Chen; Daniela Salvemini; Tadeusz P Karcz; Donald N Cook; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2021-03-31       Impact factor: 7.446

5.  Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy.

Authors:  Firas Al-Zubaydi; Dayuan Gao; Dipti Kakkar; Shike Li; Jennifer Holloway; Zoltan Szekely; Nancy Chan; Shicha Kumar; Hatem E Sabaawy; Susan Love; Patrick J Sinko
Journal:  Drug Deliv Transl Res       Date:  2021-02-15       Impact factor: 4.617

6.  Novel phenolic antimicrobials enhanced activity of iminodiacetate prodrugs against biofilm and planktonic bacteria.

Authors:  Danica J Walsh; Tom Livinghouse; Greg M Durling; Adrienne D Arnold; Whitney Brasier; Luke Berry; Darla M Goeres; Philip S Stewart
Journal:  Chem Biol Drug Des       Date:  2020-09-22       Impact factor: 2.817

Review 7.  Chinese medicinal herbs as potential prodrugs for obesity.

Authors:  Siu Kan Law; Yanping Wang; Xinchen Lu; Dawn Ching Tung Au; Wesley Yeuk Lung Chow; Albert Wing Nang Leung; Chuanshan Xu
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

8.  Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.

Authors:  Xinpeng Ma; Xiumei Huang; Gang Huang; Longshan Li; Yiguang Wang; Xiuquan Luo; David A Boothman; Jinming Gao
Journal:  Adv Healthc Mater       Date:  2014-02-14       Impact factor: 11.092

9.  Enrichment-triggered prodrug activation demonstrated through mitochondria-targeted delivery of doxorubicin and carbon monoxide.

Authors:  Yueqin Zheng; Xingyue Ji; Bingchen Yu; Kaili Ji; David Gallo; Eva Csizmadia; Mengyuan Zhu; Manjusha Roy Choudhury; Ladie Kimberly C De La Cruz; Vayou Chittavong; Zhixiang Pan; Zhengnan Yuan; Leo E Otterbein; Binghe Wang
Journal:  Nat Chem       Date:  2018-05-14       Impact factor: 24.427

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.